Month: October 2025

LyondellBasell reports third quarter 2025 earnings

Written by Customer Service on October 31, 2025. Posted in Earnings Releases And Operating Results.

Net (loss) income: $(890) million, $330 million excluding identified items1 Diluted (loss) earnings per share: $(2.77) per share; $1.01 per share excluding identified items EBITDA: $(480) million, $835 million excluding identified items Non-cash asset write-downs: $1,202 million Cash from operating activities: $983 million Strong cash conversion2 of 135% during 3Q25 Returned $443 million to shareholders during 3Q25 through dividends Continued to navigate the cycle with operational and financial discipline:Cash Improvement Plan remains on track to deliver target of $600 million3 for 2025 Operational improvements from higher rates for Hyperzone PE and Channelview PO/TBA exceeding benchmark for nameplate operating rate Advanced Polymers Solutions portfolio transformation and increased customer satisfaction driving business improvement European...

AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

Written by Customer Service on October 31, 2025. Posted in Public Companies.

MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days. About AirSculpt AirSculpt...

Castellum, Inc. Announces the Award of a $66.2 million Full and Open Contract to its SSI Subsidiary

Written by Customer Service on October 31, 2025. Posted in Public Companies.

Castellum, Inc. Announces the Award of a $66.2 million Full and Open Contract to its SSI SubsidiaryCastellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”) announces that its Specialty Systems, Inc. (“SSI”) subsidiary has been awarded a $66.2 million full and open, five year contract for logistics, engineering, cyber support services needed in support of the Naval Air Warfare Center Aircraft Division (“NAWCAD”) Lakehurst (“LKE”) Mission Operations & Integration (“MO&I”) Department – www.castellumus.comVIENNA, Va., Oct. 31, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or “CTM”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its Specialty Systems, Inc. (“SSI”) subsidiary has been awarded a $66.2...

Cenovus announces third-quarter 2025 results

Written by Customer Service on October 31, 2025. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Oct. 31, 2025 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) today announced its third-quarter 2025 financial and operating results. The company generated approximately $2.1 billion in cash from operating activities, $2.5 billion of adjusted funds flow and $1.3 billion of free funds flow. Operating results in the quarter included record Upstream production of 832,900 barrels of oil equivalent per day (BOE/d)1 and record Downstream crude throughput of 710,700 barrels per day (bbls/d), representing an overall utilization rate of 99%. HighlightsHighest recorded Upstream production of 832,900 BOE/d in the third quarter, including record production of approximately 642,800 BOE/d from the Oil Sands segment. Highest recorded U.S. Refining crude throughput of 605,300 bbls/d, representing a utilization...

Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030

Written by Customer Service on October 31, 2025. Posted in Mergers And Acquisitions.

Us Orphan Drug Rare Disease Market Offers US$ 190 Billion Opportunity Highlights Kuick Research Delhi, Oct. 31, 2025 (GLOBE NEWSWIRE) — Kuick Research announces the release of its latest study on the US Orphan Drug Market, offering investors, venture capital firms, and equity strategists a detailed and actionable perspective on one of the most resilient and rapidly expanding segments of the biopharmaceutical industry. The report, constructed from an integrated research framework, encapsulates the financial, regulatory, and scientific dynamics driving the evolution of this market. Based on an extensive review of designated orphan products, pricing benchmarks, and clinical pipelines, the study provides an exhaustive investment intelligence map for those seeking exposure to the rare disease therapeutics domain. US Orphan Designated...

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

Written by Customer Service on October 31, 2025. Posted in Public Companies.

STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial with the company’s cell therapy BT-101 targeting the rare bone disease Osteogenesis imperfecta. The new results comprise two-year follow-up data from the trial and were selected for presentation at the prestigious 15th International Conference on Osteogenesis imperfecta (OI) in Hong Kong, October 29–31. BOOST Pharma, a clinical-stage biopharmaceutical company, is advancing BT-101 as a innovative stem cell therapy for the treatment of infants born with the congenital disease osteogenesis imperfecta (OI), a condition characterized by fragile bones, constant fractures and deformities of bones. The treatment is designed to address the...

AS Tallinna Vesi held an investor conference webinar to introduce the results of the third quarter of 2025

Written by Customer Service on October 31, 2025. Posted in Earnings Releases And Operating Results.

Today, on 31 October 2025, AS Tallinna Vesi held an investor conference webinar where Chairman of the Management Board, Chief Executive Officer Aleksandr Timofejev, and Member of the Management Board, Chief Financial Officer Taavi Gröön, introduced the performance of the 3rd quarter of 2025. We thank all the participants! Webinar recording is available here and the presentation is available here. AS Tallinna Vesi´s financial and operational results for the 3rd quarter of 2025 are available here.Additional information: Taavi GröönChief Financial OfficerAS Tallinna Vesi(+372) 626 2200taavi.groon@tvesi.ee

Result of the auction of treasury bills on 31 October 2025

Written by Customer Service on October 31, 2025. Posted in Public Companies.

Bids, sales, stop-rates and prices are presented in the table below: ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 20086 DKT 02/12/25 IV 200 100 1.60 100 % 99.875798 20169 DKT 03/03/26 I 10,100 10,100 1.62 100 % 99.4674Total 10,300 10,200 The sale will settle 04 November 2025.

Magna Announces Third Quarter 2025 Results

Written by Customer Service on October 31, 2025. Posted in Earnings Releases And Operating Results.

Strong execution and operational excellence drove improved performance Year-over-year comparison (third quarter of 2025 versus third quarter of 2024):Sales increased 2% to $10.5 billion, supported by a 3% rise in global light vehicle production Income from operations before income taxes was $473 million, down 32%, as the prior year included recognition of Fisker deferred revenue as Other income Adjusted EBIT increased 3% to $613 million, with a 10 basis-point improvement in Adjusted EBIT margin Diluted earnings per share were $1.08; Adjusted diluted earnings per share rose 4% to $1.33Increase 2025 outlook for Sales, Adjusted EBIT Margin, and Adjusted Net Income attributable to Magna, reflecting confidence in our strategic positioning and execution Board approved Normal Course Issuer Bid to purchase up to 10% of our public float...

Form 8.3 – [IDOX PLC – 30 10 2025] – (CGWL)

Written by Customer Service on October 31, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree IDOX PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

Month: October 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals